Skyline will use TrovaGene's nucleophosmin protein mutation, which is found in around 35 percent of acute myeloid leukemia patients and is associated with good disease prognosis, in its Affymetrix-manufactured AMLprofiler in vitro diagnostic.
Skyline Diagnostics will use the NPM1 biomarker technology in a microarray testing service to stratify AML patients.
TrovaGene is developing molecular diagnostics based on its transrenal nucleic acid technology.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.